Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07379684

A Study of Amicidin-β Topical Solution for Patients With Surgical or Traumatic Wound Infections

The goal of this Phase 1 clinical trial is to learn about the safety profile of Amicidin-β topical solution applied directly into infected surgical or traumatic wounds during a surgical procedure. The main questions it aims to answer are:

1. Is Amicidin-β topical solution safe to test in larger clinical trials? 2. Is Amicidin-β topical solution absorbed into the bloodstream from local wound application? 3. Is Amicidin-β topical solution easy for the surgeon to use? Participants will receive either standard of care alone, or standard of care with intrawound Amicidin-β topical solution for the management of their wound infection. Researchers will compare these two groups (standard of care alone to standard of care with Amicidin-β topical solution) to see if there are any study drug-related adverse effects.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–79 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Lundquist Institute, Torrance, California, United States

Loading trial locations.

About this study

This is a Standard of Care (SOC)- controlled study of approximately 44 patients divided into three sequential cohorts of 8, 12, and 24 patients. Within each sequential cohort, patients will be randomized to SOC only or to SOC plus Amicidin-β topical solution in a 1:3 ratio.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Main Inclusion Criteria:

  • Body Mass Index between 18.5 kg/square meter and 39.9kg/square meter
  • Surgical or traumatic wound determined by the Investigator to be infected within 90 days of surgery or trauma, with longest dimension between 3 and 15 cm. The diagnosis should include one or more of the following signs or symptoms:
  • Purulent drainage
  • Erythema
  • Surrounding induration
  • Fever or localized heat surrounding the wound
  • Reported localized pain or localized tenderness on examination
  • Infected surgical or traumatic wound that is determined by the Investigator to required an interventional procedure, such as incision, drainage, irrigation, and/or debridement.
  • If female of childbearing potential, must have been practicing an acceptable method of birth control as judged by the Investigator for at least one month prior to enrollment.
  • Females of childbearing potential must agree that for the entire duration of the study (about 30 days), they will either practice true abstinence consistent with their preferred and usual lifestyle, or use double contraceptive methods.

Main Exclusion Criteria:

Patients with any of the following will be excluded:

  • Surgical or traumatic wound associated with surrounding cellulitis extending ≥10 cm from the wound edge
  • Confirmed necrotizing fasciitis or gangrenous ulcer
  • Multiple surgical or traumatic wound infections at different sites
  • Surgical or traumatic wound infection overlying bone fracture, with radiological evidence of non-union
  • Surgical or traumatic wound infection with open peritoneal cavity
  • Surgical or traumatic wound infection extending to an organ space
  • Surgical or traumatic wound infection extending to implanted surgical hardware or protesis. Note: surgical drains and packing are permitted
  • Surgical or traumatic wound infection involving head and neck
  • Surgical or traumatic wound infection involving burn injury
  • Suspected or confirmed osteomyelitis or septic arthritis
  • Surgical or traumatic wound infection known or suspected to be caused by fungal or mycobacterial organisms
  • Wound with diagnosis of neuropathic or diabetic foot ulcer or a previous diagnosis of moderate to severe chronic venous insufficiency of a lower extremity in patients with an infected surgical to traumatic wound of the lower extremity
  • Wound due to malignancy
  • Antibiotic therapy for an infection other than the surgical or traumatic wound infection
  • Patient requires supplemental O2 or mechanical ventilation
  • Pulse Oximetry (SpO2) reading of ≤ 92% on room air (confirmed by two additional readings ≤92% over 15 min). At geographic locations of high altitude, a lower SpO2 limit (e.g., ≤ 91%) may be used at Investigator's discretion

Treatment and study plan

Amicidin-β topical solution - 15 mL

Drug

Amicidin-β topical solution for local administration - 15 mL

Amicidin-β topical solution - 50 mL

Drug

Amicidin-β topical solution for local administration - 50 mL

Standard of Care (SOC)

Drug

Per institutional Standard Of Care

Primary outcomes

  1. Overall comparison of treatment emergent adverse events (TEAES) of combined SOC + Amicidin-β topical solution recipients to SOC only recipients across 3 cohorts.

    Time frame: From Day 1 to Day 30

Secondary outcomes

  1. Number of participants with Treatment Emergent Adverse Events (TEAEs) by severity according to the study protocol.

    Time frame: From Day 1 to Day 30

  2. Measurement of systemic absorption of Amicidin-β recipients.

    Time frame: From Day 1 to Day 3

    Systemic absorption will be assessed by single molecule array (Simoa) immunoassay measurements of patient plasma.

Study contacts

Contact information is provided by the study sponsor or research team.

Daniel J Gowen-Huang, MBA

CONTACT

[email protected]

(323) 717-0302

Michael P Bevilacqua, MD, PhD

CONTACT

[email protected]

(303) 881-5169

Sponsors and collaborators

Lead sponsor

Macro Biologics, Inc.

Industry

Collaborators

  • Biomedical Advanced Research and Development Authority
  • Germany's Federal Ministry of Education and Research (BMBF) Agreement Dated 1/30/23
  • Global Antimicrobial Resistance Innovation Fund-(GAMRIF)
  • Novo Nordisk Foundation (NNF23SA0088536)
  • UK Secretary of State for Health and Social Care ("DHSC"), Agreement dated 02/28/2023
  • US NIH Grant/Contract Award Number: HHS/BARDA OTA No. 75A50122C00028
  • Wellcome Trust 224842/Z/21/Z

Registry information

Official study title

A Phase 1 Study to Assess Safety and Tolerability of Amicidin-β Topical Solution in Adult Patients Undergoing Interventional Management of a Surgical or Traumatic Wound Infection

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jan 30, 2026
Registry last updated
Jul 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.